Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 406


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 6  |  Issue : 12  |  Page : 633-637

Saliva α-synuclein and a high extinction coefficient protein: A novel approach in assessment biomarkers of Parkinson's disease


1 Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
2 Department of Oral Medicine, College of Dentistry, Al-Mustansiriya University, Baghdad, Iraq

Date of Web Publication29-Dec-2014

Correspondence Address:
Marwan S. M. Al-Nimer
Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1947-2714.147980

Rights and Permissions
  Abstract 

Background: The pathological hallmark of Parkinson's disease (PD) is the appearance of intracytoplasmic inclusions known as Lewy bodies in which its principal component is α-synuclein. Aim: This study aimed to determine salivary α-synuclein and the extinction coefficient of the saliva protein as biomarkers of PD. Materials and Methods: This observational study was done in Department of Pharmacology, College of Medicine in cooperation with Department of Oral Medicine, College of Dentistry at Al-Mustansiriya University in Baghdad, Iraq from September 2013 to March 2014. A total number of 20 PD patients and 20 healthy subjects were enrolled in the study. Unstimulated saliva obtained from each participant obtained for determination of salivary flow rate, saliva protein and α-synuclein using enzyme linked immune sorbent assay (ELISA) technique. Results: Total saliva protein and uncontaminated protein with nucleic acids are significantly higher in PD compared with healthy subjects. The mean extinction coefficient of that protein is 27.25 M.cm -1 which significantly (P < 0.001) less than corresponding value of healthy subjects (33.48 M.cm−1 ). Saliva α-synuclein level is significantly less in PD (65 ± 52.2 pg/ml) than healthy subjects (314.01 ± 435.9 pg/ml). Conclusions: We conclude that saliva α-synuclein serves as a biomarker for PD if its level compared with healthy subjects, and a specific protein with extinction coefficient 27.25 M.cm-1 is detected in saliva of Parkinson's patients.

Keywords: Parkinson′s disease, saliva, α-synuclein


How to cite this article:
Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva α-synuclein and a high extinction coefficient protein: A novel approach in assessment biomarkers of Parkinson's disease. North Am J Med Sci 2014;6:633-7

How to cite this URL:
Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva α-synuclein and a high extinction coefficient protein: A novel approach in assessment biomarkers of Parkinson's disease. North Am J Med Sci [serial online] 2014 [cited 2019 Nov 15];6:633-7. Available from: http://www.najms.org/text.asp?2014/6/12/633/147980


  Introduction Top


Parkinson's disease (PD) is a chronic progressive neurodegenerative condition that recognized as a movement disorder. The physical signs of PD are resting tremor, rigidity on passive movement, akinesia (bradykinesia and hypokinesia), and postural instability. [1] The pathological hallmark of PD is degeneration of dopaminergic neurons that located in the substantia nigra parscompacta in the brain and the appearance of intracytoplasmic inclusions known as Lewy bodies. [2]

The principal component of Lewy bodies is α-synuclein that expressed in the neocortex, hippocampus, substantia nigra, thalamus, and cerebellum. [3] α-synuclein is a small (140 amino acid; 14 kDa) highly acidic, heat stable protein that is soluble and natively "unfolded." It tended to polymerize into fibrils, and to accumulate in pathologic inclusions, such as Lewy bodies, Lewy neuritis, and glial cytoplasmic inclusions. [4],[5],[6] α-synuclein filaments are observed in a spectrum of neurodegenerative diseases termed "synucleinopathies" and predominantly expressed in neurons of the central nervous system (CNS), where it localized to presynaptic terminals in close proximity to synaptic vesicles. A low level of α-synuclein in the cerebrospinal fluid is considered as a good biomarker for diagnosis of PD. [7]

In PD, hyposialorrhea is an early autonomic manifestation and a significant reduction of both basal (0.0964 +/− 0.08 ml/min) and stimulated (0.263 +/− 0.213 ml/min) saliva flow rate observed in patients presented with motor symptoms for less than one year. [8]

Devic et al.[9] demonstrated in the supernatant of the whole saliva anti-α-Synuclein antibody as a distinct band at 15kDa, and the anti-DJ-1 antibody protein as a two bands around 25 kDa. The rationale of doing this study based on the evidence of the presence of α-synuclein in the autonomic nerve fibers that supplied the salivary glands and the involvement of salivary glands by synucleinopathy in the early stage of PD. [10],[11] Add to this, the saliva is free from blood contamination that make it the ideal biofluid for detection this marker.

Therefore, the estimation of saliva α-synuclein level can substitute its determination in the cerebrospinal fluid. The aims of this study are to use the saliva as a biological fluid in determination the α-synuclein as a biomarker for PD and to identify the extinction coefficient of the saliva protein in patients with PD by using a simple procedure.


  Materials and Methods Top


This study was done in Department of Pharmacology, College of Medicine in cooperation with Department of Oral Medicine, College of Dentistry, Al-Mustansiriya University in Baghdad, Iraq from September 2013 to April 2014. The study was approved by the Institutional Scientific Committee and a consent form was obtained from each participant enrolled in study. The patients were allocated from Baghdad Teaching Hospital and the Public Clinics. Patients who eligible for this study were cases of PD treated with anti-Parkinson's medications, both genders and their ages ranged from 40-75 years. The criteria of inclusion were PD (primary, familial, and sporadic) of different duration of illnesses, treated with dopamine agonists and/or anticholinergic agents.

Healthy subjects of both genders were also included in the study served as control. The criteria of exclusion included: Severely debilitated patients and patients aged more than 80 or less than 15 years. A total number of 20 subjects who appeared healthy and 20 PD patients (Group II) were enrolled in the study. Specific information that related to the demographic characteristics and illness obtained from each patient. The Brain Bank Diagnostic Criteria for Parkinson's disease that established by United Kingdom Parkinson's Disease Society was used. Dental health care was assessed using (Decayed, Missing, and Filled teeth) DMF-T index. The degree of caries restoration (%) was calculated: Ratio of filled teeth (F-T) to the carious (D-T) plus filled teeth (F-T) (F-T/(D-T + F-T) × 100). The problem of drooling was assessed using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale. [12] The scale composed of 5 rates according to the drooling severity. These rates are: Normal (no problems); Slight (have too much saliva, but do not drool); Mild (have some drooling during sleep, but none when awake); Moderate (have some drooling when awake, but usually do not need tissues or a handkerchief); and Severe (have so much drooling that regularly need to use tissues or a handkerchief to protect clothes).

From each participant the un-stimulated (basal) saliva was collected. The participants asked to refrain from eating or drinking 2 hours prior to collection. The subject/patient rinsed their mouth with tap water then the saliva samples collected into disposable containers. Then centrifuged (3000 rpm) for 10 min. the supernatants were separated from samples and the volume of each saliva sample was measured, then samples of saliva were kept in Eppendroff's tube and frozen at (−20 ΊC) until use for biochemical analysis. The saliva flow rate is estimated by dividing the total collected saliva volume (ml) by the collection time (min) that was measured during sample collection. Total saliva protein was determined using Bradford's method. [13] The assay is based on the observation that the absorbance maximum for an acidic solution of Coomassie brilliant blue G-250 shifts from 465 nm to 595 nm when binding to protein occurs. The total protein concentration in saliva was calculated from the regression equation of best-fit line of human serum albumin standard carve (Absorbance = [0.022× concentration of albumin (μg)] +0.046). Protein contaminated with nucleic acids absorbed the light at wavelength 280 nm and it absorb much strongly at wavelength 205 nm when it is free from nucleic acids. The absorbance of a known volume (50μl) of saliva diluted with 4 milliliters distil water was measured at wavelengths 205 nm, 260 and 280 nm for each subject and patient. The concentration of uncontaminated protein was determined by using the following equations: [14]

The concentration of Uncontaminated protein (μg/ml) = 31 × absorbance at 205 nm Saliva α-synuclein is quantified using sandwich ELISA (Sensolyte Anti-alpha-Synuclein Quantitative ELISA (AnaSpec, Inc., USA). The wells of microtitre plate are pre-coated with anti-α Synuclein monoclonal antibodies, blocked and stabilized for long term storage. The amount of α-synuclein is quantified using rabbit polyclonal α-synuclein specific antibodies directly conjugated to horseradish peroxidase (HRP) are used to detect captured α-synuclein. The sensitivity of this test is 5 pg/ml of α- synuclein and saliva α-synuclein level was calculated by using the regression equation of the standard curve using different concentration (0-500 pg/ml) (The regression equation of the standard curve was: Absorbance at λ450 nm = 0.168 + (concentration × 0.004).

Statistical analysis

The results were expressed as number, percent, and whenever possible as mean ± standard deviation (SD) using Excel 2007. The data were analyzed using two-tailed unpaired student's t test, differences between percentages, confidence interval at 95% and simple correlation test taking P ≤ 0.05 as the lowest limit of significance.


  Results Top


[Table 1] shows the characteristics of the subjects and patients enrolled in the study. There are no significant differences between two groups regarding the gender distribution and the mean of age. The median of duration of PD is four years and 30% of cases have family history of PD. Current smoking reported in 20% of PD compared with 50% in healthy subjects; the difference reached significant (P < 0.05) level. The clinical features of PD observed in all patients despite of their treatment. Static tremor observed in 100%, rigidity in 75%, rigidity and bradykinesia in 70% of patients [Table 1]. The majority of cases are treated with a combination of levodopa and carbidopa (75%) and anticholinegic agents (70%) [Table 1]. No patient received bromocriptine or other drugs that related to dopamine-2 receptor agonists. Dysfunction of autonomic nervous system observed in PD in term of orthostatic dizziness (75%), dry mouth (65%) difficulties in swallowing (60%) and constipation (70%), whereas the urinary system disturbed in a lower percents [Table 1]. The symptom of drooling reported in 80% of cases with a variable presentation according to the severity of this symptom [Table 2]. Examination of the teeth revealed that PD have a non-significant high means of decay and missing teeth compared with healthy subjects [Table 2]. The mean number of filled teeth in Parkinson's patients is non-significantly less than corresponding mean of health subjects [Table 2]. The overall score of decay, missing and filling teeth is non-significantly higher in PD compared with healthy subjects. Caries restoration up to 50% is observed in 16 healthy subjects (80%) compared to 19 Parkinson's patient (90%) that does not reach to significant level [Table 2].
Table 1: Characteristics of the healthy subjects and Parkinson's patients

Click here to view
Table 2: Assessment of dental health using Decay, Missing, and filled (DMF) scoring and drooling

Click here to view


The overall un-stimulated saliva volume over ten minutes was less than 1 ml in 18 patients, whereas the saliva volume in healthy subjects ranged between 2.5-3.5 ml.

The total saliva protein, determined by Bradford's method is significantly (P < 0.001) higher in PD than corresponding value of healthy subjects (689.1 ± 442.7 versus 180.3 ± 137.7 μg/ml, respectively). Direct detection of uncontaminated protein with nucleic acid at λ205 nm ultraviolet (UV)-spectrophotometer shows significant (P < 0.002) high level in PD compared with healthy subjects (77.8 ± 37.9 versus 46.7 ± 16.0 μg, respectively). The extinction coefficient of uncontaminated protein that detected directly by UV spectrophotometer at λ 205nm in PD ranged between 27.08-27.40 M.cm -1 with a mean ± SD 27.25 ± 0.086 M.cm−1 which significantly (P < 0.001) less than corresponding values of healthy subjects (range: 27.42-50.72 M.cm−1 , mean ± SD: 33.48 ± 4.94 M.cm−1 ) [Figure 1]. Saliva α-synuclein level is significantly (P < 0.02) less in PD (65 ± 52.2 pg/ml) than healthy subjects (314.01 ± 435.9 pg/ml) and its mean level is about 20.7% of the mean of healthy subjects [Figure 2]. There is no significant correlation (r = 0) between the total saliva protein and saliva α-synuclein level in PD whereas an inverse non-significant correlation (r = −0.158) observed in healthy subjects.
Figure 1: Extinction coefficient of saliva uncontaminated protein in healthy subjects and Parkinson's patients

Click here to view
Figure 2: Saliva α-synuclein levels in Parkinson's patients and healthy subjects

Click here to view



  Discussion Top


The results of this study show significant low saliva α-synuclein level in Parkinson's patients. The significant high saliva protein level in Parkinson's patients characterized by extinction coefficient of 27.4 M.cm−1 at λ 205 nm. In respect to the characteristics of subjects and patients enrolled in this study, there is no significant difference in age between healthy subjects and PD patients. Therefore, the effect of ageing on the saliva determinants does not bias the results obtained in this study. Family history of PD reported in one third of the cases in this study. This observation in agreement with others who found that most cases of neurodegenerative disease are not explained by Mendelian inheritance of known genetic variants, but instead are thought to have a complex etiology with numerous genetic and environmental factors contributing to susceptibility. [15] One significant characteristic of Parkinson's patients is low frequency of smoking. Chang et al. (2014) mentioned in their review that cigarette smoking associated with reduced Parkinson's pathology in post-mortem brains. [16] Autonomic nervous system dysfunction is reported in all patients enrolled in this study and presented in different organs and systems. This finding is in agreement with Perez-Lloret et al.[17] who highlighted different medications to treat sialorrhea, constipation, orthostatic hypotension, urinary incontinence, sexual dysfunction. The total small volume of saliva that obtained from PD patient may be attributed to ageing, the disease itself and to the adverse effects of medications. [18] Drooling is reported in 16 out of 20 patients in which this finding is in agreement with other studies. [19]

Hyposalivation played a role in alteration the buffer capacity of saliva leading to increase dental caries around the neck of the teeth and this explains the non- significant high DMF scoring in this study. [20],[21] The significant high salivary protein in PD was previously reported and it did not influenced by the medications that prescribed to the patients. Significant high level of uncontaminated protein with nucleic acid run in parallel with significant increase in total protein and it expressed unique extinction coefficient of 27.25 M.cm−1 . Salivary α-synuclein level is significantly less in PD patients than healthy and its mean level is about 20.7% of the mean of healthy subjects. Hong et al.[7] demonstrated, in a large cohort study included patients with PD and controls, a low level of α-synuclein in cerebrospinal fluid of Parkinson's patients. Several groups have examined serum/plasma concentrations of α- synuclein as potential biomarkers of Parkinson's disease but the major drawback in assessing serum/plasma α- synuclein levels is the fact that 95% of total blood α- synuclein derived from red blood cells. Therefore, the measurement of α- synuclein in saliva provides an advantages over other biological fluids because the possibility of blood contamination can be avoided and the sample of saliva be readily obtained. In one pioneer work, Wang et al.[22] demonstrated circular dichroism spectra of the soluble tetramer α- synuclein construct exhibit negative bands at 222 nm and 208 nm, and a positive band at 193 nm. Limitations of the study included small sample size and variations in duration of disease.


  Conclusion Top


We conclude that saliva α-synuclein serves as a biomarker for PD if its level compared with healthy subjects, and a specific protein with extinction coefficient 27.5 M.cm-1 is detected in saliva of Parkinson's patients.

 
  References Top

1.
Louis ED, Bennett DA. Mild parkinsonian signs: An overview of an emerging concept. Mov Disord 2007;22:1681-8.  Back to cited text no. 1
    
2.
Beach TG, Adler CH, Lue LF, Sue LI, Bachalakuir J, Henry-Watson J, et al. Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613-34.  Back to cited text no. 2
    
3.
Gründemann J, Schlaudraff F, Haeckel O, Liss B. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008;36:e38.  Back to cited text no. 3
    
4.
Maiti NC, Apetri MM, Zagorski MG, Carey PR, Anderson VE. Raman spectroscopic characterization of secondary structure in natively unfolded proteins: Alpha-synuclein. J Am Chem Soc 2004;126:2399-408.  Back to cited text no. 4
    
5.
Bonini NM, Giasson BI. Snaring the function of alpha-synuclein. Cell 2005;123:359-61.  Back to cited text no. 5
    
6.
Wu KP, Kim S, Fela DA, Baum J. Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: Implication for aggregation. J Mol Biol 2008;378:1104-15.  Back to cited text no. 6
    
7.
Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-26.  Back to cited text no. 7
    
8.
Cersósimo MG, Tumilasci OR, Raina GB, Benarroch EE, Cardoso EM, Micheli F, et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 2009;150:150-1.  Back to cited text no. 8
    
9.
Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary α-synuclein and DJ-1: Potential biomarkers for Parkinson›s disease. Brain 2011;134:e178.  Back to cited text no. 9
    
10.
Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al., Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.  Back to cited text no. 10
    
11.
Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-13.  Back to cited text no. 11
    
12.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al., Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-70.  Back to cited text no. 12
    
13.
Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.  Back to cited text no. 13
    
14.
Stoscheck CM. Quantitation of protein. Methods Enzymol 1990;182:50-68.  Back to cited text no. 14
    
15.
Clarimón J, Kulisevsky J. Parkinson's disease: From genetics to clinical practice. Curr Genomics 2013;14:560-7.  Back to cited text no. 15
    
16.
Chang RC, Ho YS, Wong S, Gentleman SM, Ng HK. Neuropathology of cigarette smoking. Acta Neuropathol 2014;127:53-69.  Back to cited text no. 16
    
17.
Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs 2013;18:39-53.  Back to cited text no. 17
    
18.
Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson's disease: Prevalence and occurrence before motor symptoms. J Neurol 2013;260:1332-8.  Back to cited text no. 18
    
19.
Rana AQ, Khondker S, Kabir A, Owalia A, Khondker S, Emre M. Impact of cognitive dysfunction on drooling in Parkinson's disease. Eur Neurol 2013;70:42-5.  Back to cited text no. 19
    
20.
Cicciù M, Matacena G, Signorino F, Brugaletta A, Cicciù A, Bramanti E. Relationship between oral health and its impact on the quality life of Alzheimer's disease patients: A supportive care trial. Int J Clin Exp Med 2013;6:766-72.  Back to cited text no. 20
    
21.
Pradeep AR, Singh SP, Martande SS, Raju AP, Rustagi T, Suke DK, et al. Clinical evaluation of the periodontal health condition and oral health awareness in Parkinson's disease patients. Gerodontology 2013.  Back to cited text no. 21
    
22.
Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 2011;108:17797-802.  Back to cited text no. 22
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2]


This article has been cited by
1 Skin Fibroblasts as the Object for Clinical Diagnosis of Parkinson’s Disease in Persons of Different Ages
V. A. Zuev,A. S. Dyatlova,N. S. Lin’kova,I. M. Kvetnoi,N. N. Belushkina,V. A. Pal’tsev
Bulletin of Experimental Biology and Medicine. 2019; 167(1): 177
[Pubmed] | [DOI]
2 Oligomeric a-synuclein is increased in basal tears of Parkinson’s patients
Sarah F Hamm-Alvarez,Curtis T Okamoto,Srikanth R Janga,Danielle Feigenbaum,Maria C Edman,Daniel Freire,Mihir Shah,Raveena Ghanshani,Wendy J Mack,Mark F Lew
Biomarkers in Medicine. 2019;
[Pubmed] | [DOI]
3 Salivary alpha-synuclein in the diagnosis of Parkinsonæs disease and Progressive Supranuclear Palsy
Giorgio Vivacqua,Antonio Suppa,Romina Mancinelli,Daniele Belvisi,Andrea Fabbrini,Matteo Costanzo,Alessandra Formica,Paolo Onori,Giovanni Fabbrini,Alfredo Berardelli
Parkinsonism & Related Disorders. 2019;
[Pubmed] | [DOI]
4 Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson’s Disease
Fen Xie,Xiaoya Gao,Wanlin Yang,Zihan Chang,Xiaohua Yang,Xiaobo Wei,Zifeng Huang,Huifang Xie,Zhenyu Yue,Fengli Zhou,Qing Wang
ACS Chemical Neuroscience. 2019;
[Pubmed] | [DOI]
5 a-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease
Zhentang Cao,Yufeng Wu,Genliang Liu,Ying Jiang,Xuemei Wang,Zhan Wang,Tao Feng
Neuroscience Letters. 2019; 696: 114
[Pubmed] | [DOI]
6 Salivary alpha-synuclein as a biomarker for Parkinson’s disease: a systematic review
Anastasia Bougea,Christos Koros,Leonidas Stefanis
Journal of Neural Transmission. 2019;
[Pubmed] | [DOI]
7 Detection of a-Synuclein in Saliva: The Importance of Preanalytical Assessment
Giorgio Vivacqua,Romina Mancinelli,Daniele Belvisi,Antonio Suppa,Alfredo Berardelli
Movement Disorders. 2018; 33(6): 1029
[Pubmed] | [DOI]
8 The Exosomal/Total a-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients
Silvia Cerri,Cristina Ghezzi,Maria Sampieri,Francesca Siani,Micol Avenali,Gianluca Dornini,Roberta Zangaglia,Brigida Minafra,Fabio Blandini
Frontiers in Cellular Neuroscience. 2018; 12
[Pubmed] | [DOI]
9 Saliva biomarkers in neurological disorders: A “spitting image” of brain health?
Emma Louise Walton
Biomedical Journal. 2018;
[Pubmed] | [DOI]
10 Proteome characterization in various biological fluids of Trypanosoma brucei gambiense-infected subjects
Julien Bonnet,Camille Garcia,Thibaut Leger,Marie-Pauline Couquet,Philippe Vignoles,Gedeao Vatunga,Joseph Ndungæu,Clotilde Boudot,Sylvie Bisser,Bertrand Courtioux
Journal of Proteomics. 2018;
[Pubmed] | [DOI]
11 Salivary biomarkers for the diagnosis and monitoring of neurological diseases
Raymond Farah,Hayat Haraty,Ziad Salame,Youssef Fares,David M. Ojcius,Najwane Said Sadier
Biomedical Journal. 2018;
[Pubmed] | [DOI]
12 Peripheral Biomarkers for Early Detection of Alzheimer’s and Parkinson’s Diseases
Thein Than Htike,Sachin Mishra,Sundramurthy Kumar,Parasuraman Padmanabhan,Balázs Gulyás
Molecular Neurobiology. 2018;
[Pubmed] | [DOI]
13 Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinsonæs disease
Wei Song,Vimal Kothari,Ana M. Velly,Marisa Cressatti,Adrienne Liberman,Mervyn Gornitsky,Hyman M. Schipper
Movement Disorders. 2018;
[Pubmed] | [DOI]
14 Saliva Liquid Biopsy for Point-of-Care Applications
Katri Aro,Fang Wei,David T. Wong,Michael Tu
Frontiers in Public Health. 2017; 5
[Pubmed] | [DOI]
15 The Systemic Synuclein Sampling Study: toward a biomarker for Parkinsonæs disease
Naomi P Visanji,Brit Mollenhauer,Thomas G Beach,Charles H Adler,Christopher S Coffey,Catherine M Kopil,Kuldip D Dave,Tatiana Foroud,Lana Chahine,Danna Jennings
Biomarkers in Medicine. 2017; 11(4): 359
[Pubmed] | [DOI]
16 Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson’s Disease
Giorgio Vivacqua,Anna Latorre,Antonio Suppa,Michela Nardi,Sara Pietracupa,Romina Mancinelli,Giovanni Fabbrini,Carlo Colosimo,Eugenio Gaudio,Alfredo Berardelli,Philipp J. Kahle
PLOS ONE. 2016; 11(3): e0151156
[Pubmed] | [DOI]
17 Recent developments in circulating biomarkers in Parkinson’s disease: the potential use of miRNAs in a clinical setting
Marcia Cristina Teixeira dos Santos,Rosie Bell,Andre Nogueira da Costa
Bioanalysis. 2016; 8(23): 2497
[Pubmed] | [DOI]
18 Alpha-Synuclein as a Biomarker for Parkinsonæs Disease
Anzari Atik,Tessandra Stewart,Jing Zhang
Brain Pathology. 2016; 26(3): 410
[Pubmed] | [DOI]
19 Laboratory assessments in the course of Parkinson’s disease: a clinician’s perspective
Thomas Müller,Horst Baas,Jan Kassubek,Peter Riederer,Peter Paul Urban,Christoph Schrader,Heinz Reichmann,Dirk Woitalla,Manfred Gerlach
Journal of Neural Transmission. 2016; 123(1): 65
[Pubmed] | [DOI]
20 Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases
Sahdeo Prasad,Amit K Tyagi,Bharat B Aggarwal
Experimental Biology and Medicine. 2016; 241(8): 783
[Pubmed] | [DOI]
21 Biomarker sources for Parkinsonæs disease: Time to shed tears?
M. Börger,S. Funke,M. Bähr,F. Grus,P. Lingor
Basal Ganglia. 2015; 5(2-3): 63
[Pubmed] | [DOI]
22 Systematic review and meta-analysis of salivary protein concentration in Parkinsonæs disease
Joseph M. Masters,Jonathan Bestwick,Thomas T. Warner,Gavin Giovannoni,Gordon B. Proctor,Alastair J. Noyce
Movement Disorders. 2015; 30(14): 1971
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and Me...
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed1709    
    Printed34    
    Emailed0    
    PDF Downloaded345    
    Comments [Add]    
    Cited by others 22    

Recommend this journal